RxDoctor Payments Data

Danilo Dona, MD

Family Medicine · Newport, MINPI 1922024637

Payments from drug & device makers

$4,797in general payments, 2019–2025

Across 301 payments — averaging $15.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$509
  • AbbVie$506
  • Bayer$350
  • Harmony Biosciences LLC$314
  • Amgen$245
  • Novo Nordisk$240
  • plus $3K from 32 others

What the payments were for

  • Food & beverage$4,75099%
  • Education$471%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,797 in reported general payments places this provider in the 90th percentile of 3,945 family medicine providers in Michigan.

See all family medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$109,112
Medicare patients
177
Services billed
1,286

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin90$110,080
OzempicSemaglutide83$96,507
Trelegy ElliptaFluticasone/Umeclidin/Vilanter88$94,239
TrulicityDulaglutide35$81,754
JanuviaSitagliptin Phosphate57$81,608
EliquisApixaban68$74,331
RybelsusSemaglutide16$30,657
JanumetSitagliptin Phos/Metformin Hcl27$20,863
XareltoRivaroxaban12$15,997
MounjaroTirzepatide14$15,023
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate27$10,553
Tiotropium Bromide16$9,716
Lantus SolostarInsulin Glargine,hum.Rec.Anlog64$9,109
Albuterol Sulfate HfaAlbuterol Sulfate190$8,068
SymbicortBudesonide/Formoterol Fumarate16$6,805

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$240$127,16499 claims
Boehringer IngelheimJardiance$30$110,08090 claims
MerckJanuvia, Janumet$117$102,47184 claims
Lilly USA, LLCTrulicity, Mounjaro$509$96,77849 claims
GSKTrelegy Ellipta$185$94,23988 claims
PfizerEliquis$218$74,33168 claims
AstraZenecaSymbicort$217$6,80516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,945 family medicine providers in Michigan.

Other family medicine in Newport

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →